Innovative Medicines & Oncology Practice during Covid at MENA Regions Policy analysis

Abdalla Abotaleb PhD

WHO Project Manager Health, policy analysis expert & Founder of MENA Network of Biologicals Stakeholders

ABSTRACT

Oncology practice during COVID-19 pandemic faced many challenges one of the major challenges is adaptation of treatment protocols for achieving following objectives. Managing system capacity, Enhancement of patient’s outcomes (quality of life – economic value – clinical effectiveness). And utilizing the resources during this hard times. Previous objectives raised many questions about nature of treatment protocols should be implemented during COVID-19. Pandemic and how innovative medicines can achieve the previous objectives.

*Corresponding author
Abdalla Abotaleb PhD, Health policy analysis expert Founder of MENA Network of Biologicals Stakeholders. E-mail: thepharmacist7777@gmail.com

Received: October 09, 2020; Accepted: October 14, 2020; Published: October 23, 2020

Methods Integration Analysis between International Guidelines Like (ESMO, ASCO, NHS, WHO) and local guidelines. local survives with local oncologist at previous countries plus quality of life questionnaires for the patients were conducted. Cost Analysis from health systems for all oncology expenditures. Results Innovative medicines had positive impact on Enhancement of patient’s outcomes and resources utilization via implementation efficient Periodization criteria

CONCLUSION Innovative medicines protocols changed the oncology practice during COVID-19 through Dynamic & efficient prioritization criteria which leaded to patient’s outcomes (quality of life – economic value – clinical effectiveness) enhancement plus Resources utilization.

Objectives
Oncology practice during COVID-19 pandemic faced many challenges one of the major challenges is adaptation of treatment protocols for achieving following objectives. Managing system capacity, Enhancement of patient’s outcomes (quality of life – economic value – clinical effectiveness). And utilizing the resources during this hard times. Previous objectives raised many questions about nature of treatment protocols and policies should be implemented during (COVID-19) Pandemic and how innovative medicines can achieve the previous objectives. At MENA countries (Algeria, Morocco, Egypt, Lebanon, KSA, UAE and Turkey)

Methods Integration analysis between International guidelines like (ESMO, ASCO, WHO) and local guidelines local survives with local oncologist at previous countries plus quality of life questionnaires for the patients were conducted. Cost Analysis from health systems for all oncology expenditures. One way sensitivity analysis was conducted for all parameters affecting on practice adaptation to ensure validity and accuracy

Results
Innovative medicines had positive impact on Enhancement of patient’s outcomes and resources utilization via implementation efficient Periodization criteria as following

![Quality of life for Breast cancer patients using Innovative treatments](image1.png)

![Quality of life for Lung cancer patients using Innovative treatments](image2.png)

![Quality of life for HCC patients using Innovative treatments](image3.png)
Discussion
This Research analyzing the impact on innovative medicines on oncology practice and patient's outcomes (quality of life – economic value – clinical effectiveness) during COVID-19 pandemic and what were the major Elements for that adaptation for giving recommendations to all stake holders at oncology field about how practice and system response to pandemic case in order to share knowledge to enhance system performance.

Conclusion
Innovative medicines protocols changed the oncology practice during COVID-19 through Dynamic & efficient prioritization criteria which leaded to patient’s outcomes (quality of life – economic value – clinical effectiveness) enhancement plus Resources utilization [1-5].

Conflict of Interest
No conflict of interest

References
3. ESMO clinical guidelines for the management of non-coronavirus patients.